The Association of Anticoagulation Intensity with Outcomes in Hospitalized COVID-19 Patients

Table 2

Medical treatments for COVID-19 infection.

Treatment	Total (n = 915)	Standard-dose prophylaxis (n = 813)	High-dose prophylaxis (n = 32)	Therapeutic anticoagulation (n = 70)	value
Biologic, n (%)	280 (30.6)	243 (29.9)	15 (46.9)	22 (31.4)	0.1311
Dexamethasone, n (%)	43 (4.7)	36 (4.4)	3 (9.4)	4 (5.7)	0.2601
Remdesivir, n (%)	37 (4)	29 (3.6)	4 (12.5)	4 (5.7)	0.0328
Azithromycin, n (%)	438 (47.9)	398 (49)	13 (40.6)	27 (38.6)	0.1832
Hydroxychloroquine, n (%)	556 (60.8)	511 (62.9)	10 (31.3)	35 (50)	0.0003

Treatments patients underwent during hospitalization. Biologic is a conglomerate of IL-6 receptor antagonists (sarilumab or tocilizumab), IL-1 antagonist (anakinra), or any other monoclonal antibody that was used. Data are n (%) where n is the total number of patients. values comparing all three anticoagulation groups are from Fisher’s exact test.